<DOC>
	<DOC>NCT00040144</DOC>
	<brief_summary>The purpose of this study is to determine the safety and antiviral HBV activity of ACH126, 433 (b-L-Fd4C) in the treatment of adults with lamivudine-resistant chronic Hepatitis B.</brief_summary>
	<brief_title>Safety and Antiviral Study of ACH126, 433 (b-L-Fd4C) in Adults With Lamivudine-resistant Chronic Hepatitis B</brief_title>
	<detailed_description>Evaluation of safety and antiviral activity of 3 dose levels of ACH126, 443 over a twelve week treatment in the population described.</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B, Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Inclusion Criteria Adults ≥ 18 years of age Chronic HBV infection, known to be HbsAg positive ≥ 6 months On lamivudine, either 100 or 150 mg daily for the treatment of chronic hepatitis B infection and Exhibit a 23 log decrease in HBV DNA levels followed by a rebound of at least 1.5 log HBV DNA or Achieved an HBV DNA level of &lt;10,000 copies/mL HBV DNA on at least 2 occasions and have rebounded to &gt; 100,000 copies/mL HBV DNA, or Have a demonstrable 3TC resistant genotype regardless of treatment history. HBeAG positive HIV negative Serum ALT ≥1.5 and ≤10x times upper limit of normal HGB ≥10g/dl or HCT ≥30% (in the absence of blood transfusions or erythropoietin treatment in the preceding two weeks) Platelet count &gt;75,000/mm(^3), (in the absence of ongoing GCSF therapy) Serum creatinine &lt;1.1 times upper limit of normal (ULN) Negative radiologic screening test (ultrasound, CT scan or MRI) for hepatocellular carcinoma (HCC) within 6 months prior to entry PT/INR&lt;2 Subjects of reproductive capability must utilize an approved forms of birth control All women of childbearing capability must have a negative serum or urine pregnancy test (minimum sensitivity of 24 IU/L of bHCG) within 72 hours prior to the start of study medication Subjects must be able to provide written informed consent Subject must be available for followup for a period of 20 weeks Exclusion Criteria HIV infection Hepatitis C coinfection Alcohol abuse Pregnancy or breastfeeding Inability to tolerate oral medication Any clinical condition or prior therapy that, in the Investigator's opinion, would make the subject unsuitable for the study or unable to comply with the dosing requirements Use of any investigational drug Patients with decompensated liver disease Use of any concomitant herbal treatments</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>E-Antigen positive,</keyword>
	<keyword>Lamivudine-Resistant Chronic Hepatitis B,</keyword>
	<keyword>Achillion</keyword>
</DOC>